Education and Training
- Ph.D., Duke University, 1999
Jin, Genglin, Christopher J. Pirozzi, Lee H. Chen, Giselle Y. Lopez, Christopher G. Duncan, Jie Feng, Ivan Spasojevic, Darell D. Bigner, Yiping He, and Hai Yan. “Mutant IDH1 is required for IDH1 mutated tumor cell growth.” Oncotarget 3, no. 8 (August 2012): 774–82. https://doi.org/10.18632/oncotarget.577.
Rajic, Zrinka, Artak Tovmasyan, Ivan Spasojevic, Huaxin Sheng, Miaomiao Lu, Alice M. Li, Edith B. Gralla, David S. Warner, Ludmil Benov, and Ines Batinic-Haberle. “A new SOD mimic, Mn(III) ortho N-butoxyethylpyridylporphyrin, combines superb potency and lipophilicity with low toxicity.” Free Radic Biol Med 52, no. 9 (May 1, 2012): 1828–34. https://doi.org/10.1016/j.freeradbiomed.2012.02.006.
Miriyala, Sumitra, Ivan Spasojevic, Artak Tovmasyan, Daniela Salvemini, Zeljko Vujaskovic, Daret St Clair, and Ines Batinic-Haberle. “Manganese superoxide dismutase, MnSOD and its mimics.” Biochim Biophys Acta 1822, no. 5 (May 2012): 794–814. https://doi.org/10.1016/j.bbadis.2011.12.002.
Walko, Christine M., Austin J. Combest, Ivan Spasojevic, Angela Y. C. Yu, Shriya Bhushan, J Heyward Hull, Janelle Hoskins, et al. “The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients.” Cancer Chemother Pharmacol 69, no. 5 (May 2012): 1189–96. https://doi.org/10.1007/s00280-011-1815-5.
Pretty, Jack R., Thomas H. Connor, Ivan Spasojevic, Kristine S. Kurtz, Jeffrey L. McLaurin, Clayton B’Hymer, and D Gayle Debord. “Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment.” J Oncol Pharm Pract 18, no. 1 (March 2012): 23–36. https://doi.org/10.1177/1078155210389215.
Batinic-Haberle, I., I. Spasojevic, H. M. Tse, A. Tovmasyan, Z. Rajic, D. K. S. Clair, Z. Vujaskovic, M. W. Dewhirst, and J. D. Piganelli. “Erratum: Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities (Amino Acids DOI: 10.1007/s00726-010-0603-6).” Amino Acids 42, no. 1 (January 1, 2012): 115–16. https://doi.org/10.1007/s00726-010-0821-y.
Il’yasova, Dora, Ivan Spasojevic, Karel Base, Haoyue Zhang, Frances Wang, Sarah P. Young, David S. Millington, Ralph B. D’Agostino, and Lynne E. Wagenknecht. “Urinary F2-isoprostanes as a biomarker of reduced risk of type 2 diabetes.” Diabetes Care 35, no. 1 (January 2012): 173–74. https://doi.org/10.2337/dc11-1502.
Batinic-Haberle, Ines, Ivan Spasojevic, Hubert M. Tse, Artak Tovmasyan, Zrinka Rajic, Daret K. St Clair, Zeljko Vujaskovic, Mark W. Dewhirst, and Jon D. Piganelli. “Design of Mn porphyrins for treating oxidative stress injuries and their redox-based regulation of cellular transcriptional activities.” Amino Acids 42, no. 1 (January 2012): 95–113. https://doi.org/10.1007/s00726-010-0603-6.
Oberley-Deegan, Rebecca E., Joshua J. Steffan, Kyle O. Rove, Kathryn M. Pate, Michael W. Weaver, Ivan Spasojevic, Barbara Frederick, et al. “The antioxidant, MnTE-2-PyP, prevents side-effects incurred by prostate cancer irradiation.” Plos One 7, no. 9 (2012): e44178. https://doi.org/10.1371/journal.pone.0044178.
Ye, Xiaodong, Diane Fels, Artak Tovmasyan, Katherine M. Aird, Casey Dedeugd, Jennifer L. Allensworth, Ivan Kos, et al. “Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate.” Free Radic Res 45, no. 11–12 (November 2011): 1289–1306. https://doi.org/10.3109/10715762.2011.616199.